Cell line access to revolutionize the biosimilars market [version 1; referees: 2 approved]
Biologic drugs are notoriously expensive. Biosimilars, though priced lower, are also costly. Analysis of the cost of production of biologics suggests that the cost of manufacture is in many cases less than 10% of the price in high-income countries, and less than a third of the price of biosimilars i...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2018-05-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/7-537/v1 |